European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge
Portfolio Pulse from Vandana Singh
The European Medicines Agency's Committee for Medicinal Products for Human Use has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of PTC Therapeutics Inc's Translarna for Duchenne muscular dystrophy. PTC plans to request a re-examination and the drug will remain on the market until the process is completed. Analysts from William Blair believe PTC has a chance to overturn the decision based on previous experience and positive data from studies.
September 15, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics' Translarna has received a negative opinion from the European Medicines Agency, which could impact the company's stock price. However, the company plans to request a re-examination and analysts believe the decision can be overturned.
The negative opinion from the European Medicines Agency could negatively impact PTC Therapeutics' stock price in the short term. However, the company's plan to request a re-examination and the analysts' belief that the decision can be overturned could potentially mitigate this impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100